Bridgeway Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Bridgeway Capital Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-33,800	Closed	-$118K	–	1437
2018 Q4	$118K	Sell	33,800 -50,900	-60%	-$354K	﹤0.01%	1282
2018 Q3	$854K	Buy	84,700 +8,500	+11%	+$67.8K	0.01%	956
2018 Q2	$552K	Hold	76,200	–	–	0.01%	1100
2018 Q1	$460K	Buy	+76,200	New	+$629K	﹤0.01%	1120
2016 Q4	–	Sell	-13,000	Closed	-$153K	–	1480
2016 Q3	$153K	Hold	13,000	–	–	﹤0.01%	1352
2016 Q2	$168K	Hold	13,000	–	–	﹤0.01%	1338
2016 Q1	$208K	Hold	13,000	–	–	﹤0.01%	1295
2015 Q4	$372K	Sell	13,000 -750	-5%	-$20.8K	0.01%	1148
2015 Q3	$391K	Sell	13,750 -3,250	-19%	-$120K	0.01%	1142
2015 Q2	$611K	Buy	17,000 +800	+5%	+$24.9K	0.01%	975
2015 Q1	$471K	Buy	16,200 +2,000	+14%	+$52.9K	0.01%	1116
2014 Q4	$299K	Buy	+14,200	New	+$281K	0.01%	1225

Other funds holding INSY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Bridgeway Capital Management's INSY Position: Q1 2019 in Review

Bridgeway Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 33,800 shares — an estimated $118K sold.

Bridgeway Capital Management first reported a position in INSY in Q4 2014 and held it in 12 quarters. The position peaked at $854K in Q3 2018. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

Bridgeway Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
Bridgeway Capital Management sold 33,800 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $118K.
Bridgeway Capital Management first reported a position in Insys Therapeutics, Inc. in Q4 2014 and held it in 12 quarters.
Bridgeway Capital Management's Insys Therapeutics, Inc. position peaked at $854K in Q3 2018.
98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on Bridgeway Capital Management's 13F filing for Q1 2019, filed 15 May 2019.